tradingkey.logo

MaxCyte Inc

MXCT

2.075USD

+0.035+1.72%
Horarios del mercado ETCotizaciones retrasadas 15 min
220.60MCap. mercado
PérdidaP/E TTM

MaxCyte Inc

2.075

+0.035+1.72%
Más Datos de MaxCyte Inc Compañía
MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms.
Información de la empresa
Símbolo de cotizaciónMXCT
Nombre de la empresaMaxCyte Inc
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMr. Maher Masoud, J.D.
Número de empleados114
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 29
Dirección9713 Key West Avenue,
CiudadROCKVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20850
Teléfono13015175556
Sitio Webhttps://www.maxcyte.com/
Símbolo de cotizaciónMXCT
Fecha de salida a bolsaMar 29, 2016
Director ejecutivoMr. Maher Masoud, J.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
298.33K
+10.85%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
150.58K
+24.07%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Cynthia L. Collins
Ms. Cynthia L. Collins
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Maher Masoud, J.D.
Mr. Maher Masoud, J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. William W. (Will) Brooke, J.D.
Mr. William W. (Will) Brooke, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ali Soleymannezhad
Mr. Ali Soleymannezhad
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stanley C. (Stan) Erck
Mr. Stanley C. (Stan) Erck
Non-Executive Independent Director
Non-Executive Independent Director
298.33K
+10.85%
Mr. John Joseph Johnston
Mr. John Joseph Johnston
Non-Executive Independent Director
Non-Executive Independent Director
171.16K
+20.58%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
150.58K
+24.07%
Ms. Rekha Hemrajani
Ms. Rekha Hemrajani
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Dr. Yasir B. Al-Wakeel
Dr. Yasir B. Al-Wakeel
Non-Executive Independent Director
Non-Executive Independent Director
50.58K
+136.71%
Mr. Douglas J. (Doug) Swirsky
Mr. Douglas J. (Doug) Swirsky
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
Por regiónUSD
Nombre
Ganancia
Proporción
Inside the United States
8.03M
77.32%
Outside the United States
2.36M
22.68%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Product sales
5.32M
51.16%
Licenses
4.68M
45.01%
other
397.00K
3.82%
Estadísticas de accionistas
Actualizado: jue., 24 de jul
Actualizado: jue., 24 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Cadian Capital Management LP
9.42%
BlackRock Institutional Trust Company, N.A.
6.97%
The Vanguard Group, Inc.
5.23%
Vitruvian Partners LLP
4.74%
Mirabella Financial Services LLP
3.48%
Other
70.16%
Accionistas
Accionistas
Proporción
Cadian Capital Management LP
9.42%
BlackRock Institutional Trust Company, N.A.
6.97%
The Vanguard Group, Inc.
5.23%
Vitruvian Partners LLP
4.74%
Mirabella Financial Services LLP
3.48%
Other
70.16%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
24.01%
Investment Advisor
23.62%
Hedge Fund
14.89%
Private Equity
4.83%
Research Firm
3.90%
Individual Investor
1.42%
Bank and Trust
0.71%
Pension Fund
0.16%
Insurance Company
0.03%
Other
26.41%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
294
78.23M
73.51%
-18.98M
2025Q1
308
82.56M
77.59%
-14.89M
2024Q4
308
80.42M
75.91%
-14.30M
2024Q3
300
80.65M
76.72%
-18.62M
2024Q2
297
80.25M
76.66%
-17.97M
2024Q1
302
79.09M
75.86%
-22.52M
2023Q4
303
79.97M
77.01%
-14.24M
2023Q3
292
77.05M
74.47%
-17.27M
2023Q2
284
79.82M
77.43%
-11.81M
2023Q1
275
80.19M
77.98%
-11.53M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Cadian Capital Management LP
10.03M
9.42%
+683.30K
+7.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.41M
6.97%
+63.83K
+0.87%
Mar 31, 2025
The Vanguard Group, Inc.
5.57M
5.23%
+135.98K
+2.50%
Mar 31, 2025
Vitruvian Partners LLP
5.04M
4.74%
--
--
Mar 31, 2025
Mirabella Financial Services LLP
3.70M
3.48%
--
--
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
3.55M
3.34%
-547.43K
-13.36%
Mar 31, 2025
Morgan Stanley & Co. LLC
3.44M
3.23%
+3.16M
+1117.21%
Mar 31, 2025
Mudita Advisors LLP
3.33M
3.13%
+105.03K
+3.26%
Mar 31, 2025
River Global Investors LLP
3.25M
3.06%
+1.19M
+57.73%
Dec 31, 2024
Fidelity Management & Research Company LLC
2.75M
2.59%
-180.54K
-6.15%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.03%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
iShares Biotechnology ETF
0.02%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.41%
iShares Micro-Cap ETF
Proporción0.05%
Invesco Nasdaq Biotechnology ETF
Proporción0.03%
ProShares Ultra Nasdaq Biotechnology
Proporción0.03%
Avantis US Small Cap Equity ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.02%
iShares Biotechnology ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI